Subject: Survey to understand the usage of PPI through prescription behavior of physicians in India
Gastroesophageal reflux disease (GERD) is among the most common conditions seen in ambulatory clinics and its disease burden continues to rise. A cross-sectional survey of 1000 clinicians (specialist gastroenterologists and non-specialists) across India: About 39.2% and 37.1% of patients had reported GERD and PUD respectively whereas EE occurs in almost 10% of GERD patients.
Proton pump inhibitor (PPI) therapy is the mainstay pharmacologic management for GERD, although up to 40% of patients with suspected GERD derive inadequate symptom relief with PPI. While patients with PPI non-response may not have true GERD, to begin with, a subset of PPI non-responders will have PPI refractory GERD.
The PPI and histamine-2 (H2) receptor antagonists should be used as the mainstay of GERD treatment for acid suppression, with PPIs being superior to H2-receptor (H2R) antagonists. Prokinetic agents have also been used for the treatment of GERD and dyspepsia over the years. Their mode of action includes improving lower oesophageal sphincter function, oesophageal motility, and gastric emptying. Domperidone is a common antiemetic and is widely used in children, especially in cases of acute gastroenteritis, but there is a significant lack of use in adults. Domperidone is readily accessible in Asian countries, inexpensive, and generally safe. It is a blocker dopaminergic that activates gastric motility, decreases tone, and increases the level of LES pressure.
This survey is designed to understand the usage of PPI and its place in therapy along with the prescription behavior of physicians in India.
If you agree to participate, you will need to respond to the survey questionnaire.
We hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply along with your visiting card for the accuracy of records.
|
}}){kind=logo}